Søknadsresultater og tidligere tildelinger
Resultater fra KLINBEFORSKs utlysninger publiseres på denne siden umiddelbart etter vedtak i møte mellom de administrerende direktørene for de regionale helseforetakene. Liste over tildelinger for ordinær utlysning foreligger vanligvis i november måned.
KLINBEFORSKs programmidler tildeles etter anbefaling av innstillingsliste fra programstyret og påfølgende vedtak i møte mellom de administrerende direktørene for de regionale helseforetakene. Vedtaket utføres normalt i løpet av november måned.
Nedenfor gis det en oversikt over prosjekter som har oppnådd finansiering gjennom KLINEBFORSK siden programmets oppstart i 2016. Prosjektene er gruppert i nedtrekksmenyen etter utlysningsår.
Tildeling etter åpen utlysning i 2023:
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
|---|---|---|---|
|
The effect of topical tranexamic acid on postoperative complications in soft tissue plastic surgery. A multicenter randomized controlled trial |
Kjersti Ausen | St. Olavs Hospital HF | 9,6 |
|
Multicentre triple blind, placebo controlled, parallel group studies of atorvastatin in respectively episodic and chronic migraine |
Knut Hagen | St. Olavs Hospital HF | 13,2 |
|
Candesartan for prevention of cluster headache (CandClus2): Two multicenter, randomized, placebo-controlled, triple blind studies in patients with the episodic or the chronic form |
Erling Andreas Tronvik | St. Olavs Hospital HF | 19,9 |
|
Surgery versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR - the SCAR trial |
Michael Bretthauer | Oslo universitetssykehus HF | 20,0 |
|
Scandinavian trial of Uncomplicated Aortic Dissection Therapy (SUNDAY Trial) |
Eric Dorenberg | Oslo universitetssykehus HF | 10,9 |
|
The Safety of Intravenous thrombolysis in acute ischemic stroke patients with recent ingestion of Factor Xa-inhibitors Trial |
Guri Hagberg | Oslo universitetssykehus HF | 20,0 |
|
Antibiotic therapy in viral airway infections |
Magnus Nakrem Lyngbakken | Akershus universitetssykehus HF | 17,5 |
|
PALLiative radiotherapy in symptomatic pelvic SOFT tissue tumors (PALLSOFT) |
Harald Bull Ragnum | Sykehuset Telemark HF | 20,0 |
Tildeling etter åpen utlysning i 2022:
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| Comprehensive Evaluation of Two Second-Line Therapies for Immune Thrombocytopenia – a Registry-Based Pragmatic Randomized Controlled Trial | Waleed Ghanima | Sykehuset Østfold | 19,9 |
| CRISPR-Cas9 gene therapy for STAT1 Gain-of-Function disease | Emma Haapaniemi | Oslo universitetssykehus | 19,9 |
| The NORwegian atrial fibrillation self-SCREENing trial (NORSCREEN | Sigrun Halvorsen | Oslo universitetssykehus | 19,7 |
| Can SGLT2 Inhibition Preserve Structure and Function in Transplanted Kidneys? | Trond Geir Jenssen | Oslo universitetssykehus | 17,6 |
| CAR-T cell therapy targeting Ewing Sarcoma | Jon Amund Kyte | Sykehuset i Vestfold | 19,8 |
| Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye disease | Hans Olav Ueland | Helse Bergen | 19,8 |
Tildeling til prioriterte områder i 2022:
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| The Covideo study | Einar Røshol Heiervang | Sykehuset Innlandet | 18,4 |
| Comparing enhanced cognitive-behavior therapy and family-based treatment for adolescents with an eating disorder: a non-inferiority randomized controlled trial | Øyvind Rø | Oslo universitetssykehus | 20,0 |
| Interventions against long COVID in Norway – ReCover | Nina Langeland | Helse Bergen | 20,0 |
Tildeling etter utlysning i 2021:
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill. kr) |
| SAINT: SAfe INduction of labor Trial | Trond Melbye Michelsen | Oslo universitetssykehus | 20,0 |
| Registry-based randomized trial of glucocorticoid replacement in adrenal insufficiency | Eystein Sverre Husebye | Helse Bergen | 12,3 |
| NO-PARK: a phase II randomized controlled trial of nicotinamide riboside in early Parkinson’s disease | Charalampos Tzoulis | Helse Bergen | 20,0 |
| Painful Inflammatory Carpometacarpal-1 OsteoArthritis Treated with Intraarticular Steroids, Saline or Occupational therapy: The PICASSO trial | Ida Kristin Haugen | Diakonhjemmet sykehus AS | 18,7 |
| A randomized, controlled, multicenter clinical trial of immediate tumor-directed therapy versus initial conservative management in older patients with non-metastatic, high-risk prostate cancer | Sven Löffeler | Sykehuset i Vestfold | 19,3 |
Behovsidentifisert forskning:
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| Kirurgisk behandling av lipødem | Hildur Skuladottir | Haraldsplass Diakonale Sykehus | 20,0 |
| eBATTLE Obesity (eHealth BehAvioral TreaTment of adoLEscent Obesity - 2-month low-energy-diet followed by 1-yr cognitive behavioral therapy with or without semaglutide) | Jøran Hjelmesæth | Sykehuset i Vestfold | 20,0 |
Ekstraordinær bevilgning over Statsbudsjettet 2021:
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| RAM-MS | Lars Bø | Haukeland universitetssykehus | 20,0 |
| IMPRESS-Norway | Åslaug Helland | Oslo universitetssykehus | 10,0 |
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| Randomized trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab plus platinum and etoposide in extensive stage small-cell lung cancer | Bjørn Henning Grønberg | St. Olavs hospital | 19.3 |
| Evaluation of a Norwegian model of an Intensive Habilitation Program for young Children with early Brain Damage – a multicentre Randomized Controlled Trial | Jon Sverre Skranes | Sørlandet sykehus | 19.8 |
| The NO-ALS Study. Effect of Nikotinamide Riboside and Pterostilben in Amyotrophic Lateral Sclerosis | Ole-Bjørn Tysnes | Helse Bergen | 18.9 |
| Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial | Torgeir Bruun Wyller | Oslo universitetssykehus | 19.7 |
| TENecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): A randomised-controlled, double-dummy, double-blind trial of tenectecteplase vs. ASA for CRAO | Anne Hege Aamodt | Oslo universitetssykehus | 6.3 |
| IMPRESS-Norway – Improving public cancer care by implementing precision medicine in Norway | Åslaug Helland | Oslo universitetssykehus | 50.0 |
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| Study of mesenchymal autologous stem cells as regenerative treatment for multiple sclerosis (SMART-MS) | Lars Bø | Helse Bergen | 12.3 |
| Ocrelizumab vs Rituximab off-label at the onset of relapsing MS disease: The OVERLORD MS-study | Kjell-Morten Myhr | Helse Bergen | 19.2 |
| The Norwegian Tenecteplase Stroke Trial 2 (NOR-TEST 2) | Halvor Næss | Helse Bergen | 19.9 |
| Durvalumab after radiotherapy - the DART-study | Åslaug Helland | Oslo universitetssykehus | 14.2 |
| Faecal transplantation for irritable bowel syndrome - first Phase III clinical trial | Rasmus Goll | Universitetssykehuset Nord-Norge | 19.4 |
| Repeated advanced cognitive training in MCI (the REACT-MCI study) | Susanne M. Sørensen Hernes | Sørlandet sykehus | 19.8 |
| Improving treatment of anterior curciate ligament tears in NORWAY with register-RCTs | Rune Bruhn Jacobsen | Akershus universitetssykehus | 17.8 |
| Dietary interventio to delay deterioration if neuronal function in Ataxia Telangiectasia | Hilde Nilsen | Akershus universitetssykehus | 6.4 |
| Ambroxol in early and prodromal Dementia with Lewybodies | Arvid Rongve | Helse Fonna HF | 20.0 |
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| The Norwegian Trial of Physical Exercise After Myocardial Infarction - NOREx | Kåre Bønaa | St. Olavs hospital | 20.0 |
| Acceptance and commitment therapy with and without enhanced mindfulness training for chronic pain: A randomized controlled efficacy and mediator study | Petter Christian Borchgrevink | St. Olavs hospital | 19.9 |
| Proteasome blockade to sensitize glioblastoma with unmethylated MGMT promoter to temozolomide chemotherapy | Dorota Goplen | Helse Bergen | 15.8 |
| Fecal Transplantation for Primary Clostridium Difficile Infection | Michael Bretthauer | Oslo universitetssykehus | 19.9 |
| Urine based surveillance of bladder cancer patients | Guro E. Lind | Oslo universitetssykehus | 20.0 |
| The ReSScue study; clinical and mechanistic effects of transplanting a standard cultivated gut microbiome in patients with Systemic Sclerosis | Øyvind Molberg | Oslo universitetssykehus | 19.0 |
| The REMNANT study – does early treatment of relapse increase survival in myeloma? | Fredrik H. Schjesvold | Oslo universitetssykehus | 20.0 |
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| Sphenopalatine ganglion block in chronic migraine (MIBLOCK) | Anders Mattias Linde | St. Olavs hospital | 18.7 |
| Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezing – INSTAR | Henrik Døllner | St. Olavs hospital | 20.0 |
| Immunotherapy for Hematological Malignancies- A Path to Cure | Henrik Hjorth-Hansen | St. Olavs hospital | 5.7 |
| Changing the specialist mental health care | Gerd Kvale | Helse Bergen | 20.0 |
| Improved prediction of outcome by global strain and mechanical dispersion in patients with myocardial infarction, heart failure and primary prophylactic internal defibrillator | Thor Edvardsen | Oslo universitetssykehus | 17.8 |
| BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function | Dan Atar | Oslo universitetssykehus | 15.0 |
| Establishment of Molecular profiling for Individual clinical routine Treatment decisions in Early Breast Cancer (EMIT) | Bjørn Naume | Oslo universitetssykehus | 20.0 |
| BACK-TO-BASIC - a study of the effect of infliximab on patients with long-term lower back pain and Modic changes | John-Anker Zwart | Oslo universitetssykehus | 17.9 |
| Tittel | Prosjektleder | Koordinerende institusjon | Sum (mill.kr) |
| Tenecteplase in wake-up ischaemic stroke trial – TWIST | Ellisiv B. Mathiesen | Universitetssykehuset Nord-Norge | 15.5 |
| A Phase 1b/2 clinical trial with Axl kinase inhibitor BGB324 in combination with Dabrafenib/Trametinib or Pembrolizumab in Metastatic Melanoma: Identification of predictive markers of response | Oddbjørn Straume | Helse Bergen | 17.6 |
| Randomized autologous hematopoietic stem cell transplantation vs. Alemtuzumab for patients with relapsing remitting Multiple sclerosis (RAM-MS) | Lars Bø | Helse Bergen | 20.0 |
| PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA-2) | Torbjørn Omland | Akershus universitetssykehus | 20.0 |
| The Nor-DRUM STUDY: assessing the effectiveness of tailoring infliximab treatment by therapeutic drug monitoring | Espen Andre Haavardsholm | Diakonhjemmet Sykehus AS | 12.4 |
| The ASAC-study: Acetylsalisylic Acid as Secondary Prevention in Colorectal Cancer | Bjørn Atle Bjørnbeth | Oslo universitetssykehus | 13.8 |
| The Norwegian Antibiotics for Pneumonia in Children (NAPiC) study | Håvard Ove Skjerven | Oslo universitetssykehus | 19.3 |